Studies on experimental adjuvanted influenza vaccines: Comparison of immune stimulating complexes (Iscoms™) and oil-in-water vaccines

Vaccine

Volumn 16, Issue 11-12, 1998, Pages 1243-1253

  Coulter, Alan ^a   Wong, Tuen Yee ^a   Drane, Debbie ^a   Bates, John ^a   Macfarlan, Roderick ^a   Cox, John ^a  

^a CSL LIMITED   (Australia)

Author keywords

Adjuvants; Influenza; Iscom

Indexed keywords

IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; ISCOM; QUIL A; SAPONIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CYTOTOXIC T LYMPHOCYTE; DRUG FORMULATION; EMULSION; IMMUNOSTIMULATION; INFLUENZA; INFLUENZA VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, VIRAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; EMULSIONS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INFLUENZA VACCINES; ISCOMS; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0031750845     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)80125-4     Document Type: Article

References (42)

1. Fedson, D.S., Wajda, A. and Nicol, J.P. et al. Clinical effectiveness of influenza vaccination in Manitoba. JAMA 1993, 270, 1956-1961.
2. Govaert, T.M.E., Thijs, C.T.M.C.N., Masurel, N., Sprenger, M.J.W., Dinant, G.J. and Knottnerus, J.A. The efficacy of influenza vaccination in elderly individuals: a randomized double-blind placebo-controlled trial. JAMA 1994, 272, 1661-1665.
3. Salk, J.E., Laurent, A.M. and Bailey, M.L. Direction of research on vaccination against influenza - new studies with immunologic adjuvants. Am. J. Pub. Hlth 1951, 41, 669-677.
4. Freund, J. The effect of paraffin oil and mycobacteria on antibody formation and sensitization. Am. J. Clin. Pathol. 1951, 21, 645-656.
5. Salk, J.E., Bailey, M.L. and Laurent, A.M. The use of adjuvants in studies on influenza immunization. II. Increased antibody formation in human subjects inoculated with influenza virus vaccine in a water-in-oil emulsion. Am. J. Hyg. 1952, 55, 439-456.
6. Salk, J.E., Contakos, M. and Laurent, A.M. et al. Use of adjuvants in studies on influenza immunization. 3. Degree of persistence of antibody in human subjects two years after vaccination. JAMA 1953, 151, 1169-1175.
7. Beebe, G.W., Simon, A.M. and Vivona, S. Follow-up study on army personnel who received adjuvant influenza virus vaccine 1951 -1953. Am. J. Med. Sci. 1964, 247, 385-406.
8. Davenport, F.M. Seventeen years' experience with mineral oil adjuvant influenza virus vaccines. Ann. Allerg. 1968, 26, 288-292.
9. Fukumi, H. Effectiveness and untoward reactions of oil adjuvant influenza vaccines. In: Symposium Series, Immunobiology Standard, Vol. 6. Karger, Basel, New York, 1967, p. 237.
10. Stewart-Tull, D.E.S. The assessment and use of adjuvants. In: NATO ASI Series A: Life Sciences Vol. 215. Vaccines: Recent Trends and Progress (Eds Gregoriadis, G., Allison, A.C. and Poste, G.). Plenum Press, New York, 1991, p. 85.
11. Davenport, F.M., Hennessy, A.V. and Askin, F.B. Lack of adjuvant effect of AIPO4 on purified influenza virus hemagglutinins in man. J. Immunol. 1968, 100, 1139-1140.
12. Cox, J.C. and Coulter, A.R. Advances in adjuvant technology and application. In: Animal Parasite Control Utilizing Biotechnology (Ed. Yong, W.K.). CRC Press, Boca Raton, 1992, pp. 49-112.
13. Duncan, E.S. Stewart-Tull (Ed.) The Theory and Practical Application of Adjuvants. John Wiley and Sons, Chichester, 1995.
14. Powell, M.F. and Newman, M.J. (Eds) Vaccine Design The Subunit and Adjuvant Approach. Plenum Press, New York, 1995.
15. Cox, J.C. and Coulter, A.R. Adjuvants - a classification and review of their modes of action. Vaccine 1997, 25, 248-256.
16. Hunter, R., Strickland, F. and Kezdy, F. The adjuvant activity of nonionic block polymer surfactants. I. The role of hydrophile-lipophile balance . J. Immunol. 1981, 127, 1244-1250.
17. Snippe, H., De Reuver, M.J., Strickland, F., Willers, J.M.N. and Hunter, R.L. Adjuvant effect of nonionic block polymer surfactants in humoral and cellular immunity. Int. Arch. Allergy Appl. Immunol. 1981, 65, 390-398.
18. Lubowe, I. and Wells, F.V. (Eds.) Biological role and practical uses of squalene and squalane. In: Cosmetics and the Skin. Reinhold Publishing, New York, 1964.
19. Keitel, W., Couch, R., Bond, N., Adair, S., Van Nest, G. and Dekker, C. Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant. Vaccine 1993, 11, 909-913.
20. Allison, A.C. and Byars, N.E. An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity. J. Immunol. Methods 1986, 95, 157-168.
21. Kenney, J.S., Hughes, B.W., Masada, M.P. and Allison, A.C. Influence of adjuvants on the quantity, affinity, isotype and epitope specificity of murine antibodies. J. Immunol. Methods 1989, 121, 157-166.
22. Byars, N.E., Allison, A.C., Harmon, M.W. and Kendal, A.P. Enhancement of antibody responses to influenza B virus haemagglutinin by use of a new adjuvant formulation. Vaccine 1990, 8, 49.
23. Van Nest, G.A., Steimer, K.S., Haigwood, N.L., Burke, R.L. and Ott, G. Advanced adjuvant formulations for use with recombinant subunit vaccines. In: Vaccines 92. Cold Spring Harbor Laboratory Press, F. Brown et al. (Eds). Cold Spring Harbor, New York, 1992, pp. 57-62.
24. Valensi, J.-P.M., Carlson, J.R. and Van Nest, G.A. Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. J. Immunol. 1994, 153, 4029-4039.
25. Martin, T.J. Enhanced immunogenicity of chiron biocine adjuvanted influenza vaccine in the elderly. In: Options for the Control of Influenza (Eds Brown, L.E., Hampson, A.W. and Webster, R.G.). Elsevier Science, Amsterdam, 1996, pp. 647-652.
26. Morein, B., Sundquist, B., Hoglund, S., Dalsgaard, K. and Osterhaus, A. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 1984, 308, 457-460.
27. Ramon, G. Procedes pour accroitre la production des antitoxines. Ann. Inst. Pasteur, Paris 1926, 40, 1-10.
28. Dalsgaard, K. The application of the Saponin adjuvant Quil A in foot-and-mouth disease vaccines. In: Report and Proceedings from the Symposium on Vaccine Adjuvants held in London on the 30th March, 1981. 1981, pp. 11-15.
29. Kensil, C.A., Marciani, D.J., Beltz, G.A. and Hung, C.-H. Saponin Adjuvant, Patent WO 88/09336, 1-55. Cambridge Bioscience Corporation, Cambridge, 1988.
30. Rönnberg, B., Fekadu, M. and Morein, B. Adjuvant activity of non-toxic Quillaja saponaria molina components for use in ISCOM matrix. Vaccine 1995, 13, 1375-1382.
31. Lövgren, K. The serum antibody response distributed in subclasses and isotypes after intranasal and subcutaneous immunization with influenza virus immunostimulating complexes. Scand. J. Immunol. 1988, 27, 241-245.
32. Mumford, J.A., Jessett, D., Dunleavy, U., Wood, J., Hannant, D., Sundquist, B. and Cook, R.F. Antigenicity and immunogenicity of experimental equine influenza ISCOM vaccines. Vaccine 1994, 12, 857-863.
33. Wong, T.-Y., Turner, G., Cox, J., Pye, D., Bates, J. and Coulter, A. Studies on adjuvanted influenza vaccines: a consistent murine model for evaluating vaccine efficacy. In preparation.
34. Gerhard, W., Haberman, A.M., Scherle, P.A., Taylor, A.H., Palladino, G. and Caton, A.J. Identification of eight determinants in the hemagglutinin molecule of influenza virus A/PR/8/34 (H1N1) which are recognized by class II-restricted T cells from BALB/c mice. J. Virol. 1991, 65, 364-372.
35. Wood, J.M., Schild, G.C., Newman, R.W. and Seagroatt, V. Application of an improved single-radial-immunodiffusion technique for the assay of haemagglutinin antigen content of whole virus and subunit influenza vaccines. Develop. Biol. Standard 1977, 39, 193-200.
36. Robertson, J.S., Cook, P., Attwell, A.M. and Williams, S.P. Replicative advantage in tissue culture of egg-adapted influenza virus over tissue-culture derived virus: implications for vaccine manufacture. Vaccine 1995, 13, 1583-1588.
37. Yetter, R.A., Lehrer, S., Ramphal, R. and Small, P.A.J. Outcome of influenza infection: effect of site of initial infection and heterotypic immunity. Infect. Immun. 1980, 29, 654-662.
38. Tamura, S.-I., Ito, Y. and Asanuma, H. et al. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. J. Immunol. 1992, 149, 981-988.
39. Macfarlan, R.I., Dietzschold, B. and Koprowski, H. Stimulation of cytotoxic T-lymphocyte responses by rabies virus glycoprotein and identification of an immunodominant domain. Mol. Immunol. 1986, 23, 733-741.
40. S.E. Negative Staining. Hayet, M.A. and S.E. Miller, McGraw-Hill, New York, 1990.
41. Morein, B., Lövgren, K. and Hoglund, S. Immunostimulating complex (ISCOM). In: Vaccines: Recent Trends and Progress (Eds Gregoriadis, G., Allison, A.C. and Poste, G.). Plenum Press, New York, 1989, pp. 153-161.
42. Ott, G., Barchfeld, G.L., Chernoff, D., Radhakrishnan, R., van Hoogevest, P. and Van Nest, G. MF59: design and evaluation of a safe and potent adjuvant for human vaccines. In: Vaccine Design. The Subunit and Adjuvant Approach (Eds Powell, M.F. and Newman, M.J.). Plenum Press, New York, 1995, pp. 277-296.